Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology.

Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR.

Arch Intern Med. 2002 May 27;162(10):1182-9.

PMID:
12020191
2.

Greater fish, fruit, and vegetable intakes are related to lower incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology.

Steffen LM, Folsom AR, Cushman M, Jacobs DR Jr, Rosamond WD.

Circulation. 2007 Jan 16;115(2):188-95. Epub 2006 Dec 18.

3.

Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study.

Holst AG, Jensen G, Prescott E.

Circulation. 2010 May 4;121(17):1896-903. doi: 10.1161/CIRCULATIONAHA.109.921460. Epub 2010 Apr 19.

4.

Body height and sex-related differences in incidence of venous thromboembolism: a Danish follow-up study.

Severinsen MT, Johnsen SP, Tjønneland A, Overvad K, Dethlefsen C, Kristensen SR.

Eur J Intern Med. 2010 Aug;21(4):268-72. doi: 10.1016/j.ejim.2010.03.013. Epub 2010 Apr 28.

PMID:
20603033
5.

Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromsø study.

Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB.

J Thromb Haemost. 2008 Nov;6(11):1851-7. doi: 10.1111/j.1538-7836.2008.03102.x. Epub 2008 Jul 26.

6.

Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism.

Glynn RJ, Rosner B.

Am J Epidemiol. 2005 Nov 15;162(10):975-82. Epub 2005 Oct 5.

PMID:
16207808
7.

Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis.

Prandoni P, Ghirarduzzi A, Prins MH, Pengo V, Davidson BL, Sørensen H, Pesavento R, Iotti M, Casiglia E, Iliceto S, Pagnan A, Lensing AW.

J Thromb Haemost. 2006 Sep;4(9):1891-6.

8.

Body height and risk of venous thromboembolism: The Tromsø Study.

Braekkan SK, Borch KH, Mathiesen EB, Njølstad I, Wilsgaard T, Hansen JB.

Am J Epidemiol. 2010 May 15;171(10):1109-15. doi: 10.1093/aje/kwq066. Epub 2010 Apr 23.

PMID:
20418276
9.

Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden.

Couturaud F, Kearon C, Leroyer C, Mercier B, Abgrall JF, Le Gal G, Lacut K, Oger E, Bressollette L, Ferec C, Lamure M, Mottier D; Groupe d'Etude de la Thrombose de Bretagne Occidentale (G.E.T.B.O).

Thromb Haemost. 2006 Dec;96(6):744-9.

PMID:
17139368
10.

Venous thromboembolism after spinal cord injury: incidence, time course, and associated risk factors in 16,240 adults and children.

Jones T, Ugalde V, Franks P, Zhou H, White RH.

Arch Phys Med Rehabil. 2005 Dec;86(12):2240-7.

PMID:
16344018
11.

Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents.

Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G.

Arch Intern Med. 2005 Dec 12-26;165(22):2677-82.

PMID:
16344428
12.

Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial.

Kucher N, Leizorovicz A, Vaitkus PT, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ.

Arch Intern Med. 2005 Feb 14;165(3):341-5.

PMID:
15710801
13.

Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival.

Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H, White RH.

J Clin Oncol. 2006 Mar 1;24(7):1112-8.

PMID:
16505431
14.

Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology.

Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR.

Am J Med. 2004 Jul 1;117(1):19-25.

PMID:
15210384
15.

Smoking and venous thromboembolism: a Danish follow-up study.

Severinsen MT, Kristensen SR, Johnsen SP, Dethlefsen C, Tjønneland A, Overvad K.

J Thromb Haemost. 2009 Aug;7(8):1297-303. doi: 10.1111/j.1538-7836.2009.03490.x. Epub 2009 Jun 30.

16.

Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.

Eriksson H, Lundström T, Wåhlander K, Clason SB, Schulman S; THRIVE III Investigators.

Thromb Haemost. 2005 Sep;94(3):522-7.

PMID:
16268466
17.

Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry.

Linnemann B, Zgouras D, Schindewolf M, Schwonberg J, Jarosch-Preusche M, Lindhoff-Last E.

Blood Coagul Fibrinolysis. 2008 Mar;19(2):159-65. doi: 10.1097/MBC.0b013e3282f54558.

PMID:
18277138
18.

Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism.

Simon T, Beau Yon de Jonage-Canonico M, Oger E, Wahl D, Conard J, Meyer G, Emmerich J, Barrellier MT, Guiraud A, Scarabin PY; EStrogen and THromboEmbolism Risk (ESTHER) Study Group.

J Thromb Haemost. 2006 Jan;4(1):71-6.

19.

Risk factors and clinical impact of postoperative symptomatic venous thromboembolism.

Gangireddy C, Rectenwald JR, Upchurch GR, Wakefield TW, Khuri S, Henderson WG, Henke PK.

J Vasc Surg. 2007 Feb;45(2):335-341; discussion 341-2.

20.

Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.

Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D'Aiuto G, Gulisano M, Gucciardo G, del Turco MR, Pizzichetta MA, Conforti S, Bonanni B, Boyle P, Veronesi U; Italian Tamoxifen Study Group.

Circulation. 2005 Feb 8;111(5):650-6.

Supplemental Content

Support Center